Clinical Trials
7 trialsNCT06885697 2026-06-05
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05104736 2026-05-12
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04417660 2026-04-07
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01621568 2024-09-24
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01610544 2018-07-05
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01100944 2017-08-10
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated